头颈部肿瘤IMRT后口干症时间性剂量-反应关系的内外部可推广性
研究评估121例头颈部肿瘤IMRT患者口干症的时间性剂量-反应关系的内外部可推广性。对侧和同侧腮腺平均剂量升高解释短期口干症,识别的对侧腮腺最低平均剂量阈值低于QUANTEC指南。建议将对侧腮腺平均剂量降至20Gy以下,同侧腮腺保持在25Gy左右;长期口干症较少且未建立剂量-反应关系。
要点
- 对侧和同侧腮腺平均剂量升高与IMRT后3个月口干症风险增加相关。
- 识别的对侧腮腺最低平均剂量阈值低于QUANTEC指南推荐值。
- 建议将对侧腮腺平均剂量降至20Gy以下,同侧腮腺保持在25Gy左右。
核心结论
- 对侧和同侧腮腺平均剂量升高解释头颈部肿瘤IMRT后短期口干症。
- 结果提示将对侧腮腺平均剂量降至20Gy以下,同时保持同侧腮腺在25Gy左右。
- 长期口干症较少见,该随访时间未建立剂量-反应关系。
研究设计与样本
- 研究对象为121例接受70Gy@2Gy IMRT的头颈部肿瘤患者,2006-2015年治疗,分Cohort1(55例)和Cohort2(66例)。
- 在Cohort1中进行单变量和多变量分析(多变量分析含1000个bootstrap总体),并在Cohort2中验证最佳多变量分析模型的可推广性。
- 从生成的剂量-反应曲线估计对侧和同侧腮腺最低平均剂量阈值。
主要发现
- Cohort1和Cohort2观察到的口干症发生率分别为3个月38%和47%,11-12个月19%和23%。
- 3个月口干症风险随对侧和同侧腮腺平均剂量升高而增加(Cohort1:0.17·Dmeancontra+0.11·Dmeanipsi-8.13;AUC=0.90±0.05;p=0.0002±0.002;pHL=0.22±0.23;Cohort2:AUC=0.81;p<0.0001;pHL=0.27)。
- 识别的对侧腮腺最低平均剂量阈值低于QUANTEC指南(Cohort1/Cohort2:Dmeancontra=12/19Gy;Dmeancontra, Dmeanipsi=16, 25/20, 26Gy)。
关键数值与推荐
- 对侧腮腺最低平均剂量阈值:Cohort1为12Gy,Cohort2为19Gy。
- 对侧和同侧腮腺最低平均剂量阈值组合:Cohort1为16Gy和25Gy,Cohort2为20Gy和26Gy。
- 上述阈值均低于QUANTEC指南推荐值。
临床怎么用
- 在头颈部肿瘤IMRT计划中,可考虑将对侧腮腺平均剂量降至20Gy以下以降低短期口干症风险。
- 同时保持同侧腮腺平均剂量在25Gy左右。
- 上述剂量阈值低于QUANTEC指南,临床可参考本研究结果进行优化。
局限性
- 长期口干症较少见,该随访时间未建立剂量-反应关系。
- 研究样本量有限(共121例),结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To study internal and external generalizability of temporal dose-response relationships for xerostomia after intensity-modulated radiotherapy (IMRT) for head and neck cancer, and to investigate potential amendments of the QUANTEC guidelines. MATERIAL AND METHODS: Objective xerostomia was assessed in 121 patients (nCohort1=55; nCohort2=66) treated to 70Gy@2Gy in 2006-2015. Univariate and multivariate analyses (UVA, MVA with 1000 bootstrap populations) were conducted in Cohort1, and generalizability of the best-performing MVA model was investigated in Cohort2 (performance: AUC, p-values, and Hosmer-Lemeshow p-values (pHL)). Ultimately and for clinical guidance, minimum mean dose thresholds to the contralateral and the ipsilateral parotid glands (Dmeancontra, Dmeanipsi) were estimated from the generated dose-response curves. RESULTS: The observed xerostomia rate was 38%/47% (3months) and 19%/23% (11-12months) in Cohort1/Cohort2. Risk of xerostomia at 3months increased for higher Dmeancontra and Dmeanipsi (Cohort1: 0.17·Dmeancontra+0.11·Dmeanipsi-8.13; AUC=0.90±0.05; p=0.0002±0.002; pHL=0.22±0.23; Cohort2: AUC=0.81; p<0.0001; pHL=0.27). The identified minimum Dmeancontra thresholds were lower than in the QUANTEC guidelines (Cohort1/Cohort2: Dmeancontra=12/19Gy; Dmeancontra, Dmeanipsi=16, 25/20, 26Gy). CONCLUSIONS: Increased Dmeancontra and Dmeanipsi explain short-term xerostomia following IMRT. Our results also suggest decreasing Dmeancontra to below 20Gy, while keeping Dmeanipsi to around 25Gy. Long-term xerostomia was less frequent, and no dose-response relationship was established for this follow-up time.
引用
- Thor M, Owosho AA, Clark HD, et al. Internal and external generalizability of temporal dose-response relationships for xerostomia following IMRT for head and neck cancer. Radiother Oncol. 2016. PMID: 27890427. doi:10.1016/j.radonc.2016.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。